All In MedTech

FDA Clearance Tracker · P160038

Praxis Extended RAS Panel

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 29, 2017

Approval withdrawn

Time to decision

300 days

Received Sep 2, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160038
Device name
Praxis Extended RAS Panel
Applicant location
San Diego, CA
Received
Sep 2, 2016
Decided
Jun 29, 2017
Decision
Approval withdrawn
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
25 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval for the Praxis Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The Praxis™ Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with Vectibix® (panitumumab) based on a no mutation detected test result. The test is intended to be used on the Illumina MiSeqDx® instrument.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Illumina, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.